CDKS and CKIS: Molecular targets for tissue remodelling

Nature Reviews Drug Discovery

Volumn 1, Issue 8, 2002, Pages 587-598

  Nabel, Elizabeth G ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXINDOLE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME; PROTEIN KINASE B; PROTEIN P57; RAPAMYCIN; RETINOBLASTOMA PROTEIN; STATHMIN; TACROLIMUS; THREONINE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; CYCLINE; ENZYME INHIBITOR;

ACUTE GRAFT REJECTION; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELL NUCLEUS; CELL SPECIFICITY; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; HUMAN; ORGAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; TISSUE REGENERATION; ANIMAL; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; SIGNAL TRANSDUCTION; TISSUE SURVIVAL;

EID: 0036688344     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd869     Document Type: Review

References (141)

1. Gu, Y., Turek, C. W., & Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707-710 (1993).
2. Harper, J. W. et al. The p21 CDK-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
3. El-Diery, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
4. Xiong, Y. et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704 (1993).
5. Dulic, V. et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023 (1994).
6. KIP1, a cyclin-CDK inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22 (1994).
7. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
8. Toyoshima, H. & Hunter, T. p27, a novel inhibitor of G1 cyclin/CDK protein kinase activity, is related to p21. Cell 78, 67-74 (1994).
9. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9, 639-649 (1995).
10. CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9, 650-662 (1995).
11. Chen, J. et al. Separate domains of p21 involved in the inhibition of CDK kinase and PCNA. Nature 374, 386-388 (1995).
12. CIP1. Mol. Cell. Biol. 16, 4673-4682 (1996).
13. WAF1. EMBO J. 14, 555-563 (1995).
14. WAF1 and proliferating cell nuclear antigen. Curr. Biol. 5, 275-282 (1995).
15. WAF1 gene activities. Mol. Biol. Cell 16, 1786-1793 (1996).
16. KIP1 cyclin-dependent kinase inhibitor bound to the cyclin A-CDK2 325-complex. Nature 382, 325-331 (1996).
17. Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993).
18. INK4b is a potential effector of TGFβ-induced cell cycle arrest. Nature 371, 257-261 (1994).
19. INK4b/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8, 2939-2952 (1994).
20. Hirai, H. et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15, 2672-2681 (1995).
21. ink4, Mol. Cell. Biol. 15, 2682-2688 (1995).
22. 1 cyclins. Cell 73, 1059-1065 (1996).
23. 1-phase progression. Genes Dev. 13, 1501-1512 (1999).
24. Xiong, Y., Zhang, H. & Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7, 1572-1583 (1993).
25. Tanner, F. C. et al. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82, 396-403 (1998).
26. KIP1. Genes Dev. 11, 1464-1478 (1997).
27. Rodier, G. et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20, 6672-6682 (2001).
28. KIP1. EMBO J. 16, 5334-5344 (1997).
29. Koff, A. et al. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260, 536-539 (1993).
30. KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55, 1206-1210 (1995).
31. Zhang, Y. & Lin, S. C. Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter. Biochim. Biophys. Acta 1353, 307-317 (1997).
32. KIP1, increases its protein stability. J. Biol. Chem. 275, 25146-25154 (2000).
33. KIP1 expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J. Cell Biol. 148, 543-556 (2000).
34. KIP1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol. Cell. Biol. 16, 4327-4336 (1996).
35. Hengst, L. & Reed, S. I. Inhibitors of the CIP/KIP family. Curr. Top. Microbiol. immunol. 227, 25-41 (1996).
36. KIP1 mRNA is a mechanism contributing to accumulation during growth arrest. J. Biol. Chem. 272, 7093-7098 (1997).
37. Miskimins, W. K. et al. Control of cyclin-dependent kinase inhibitor p27 expression by CAP-independent translation. Mol. Cell. Biol. 21, 4960-4967 (2001).
38. Kip1 in G1 and S phase. Nature 413, 323-327 (2001).
39. KIP1 and regulates cell cycle progression. EMBO J. 21, 3390-3401 (2002).
40. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685 (1995).
41. Feldman, R. M. et al. A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p. Cell 91, 221-230 (1997).
42. Bai, C. et al. SKP1 connects cell cycle regulation to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274 (1996).
43. Skowyrs, D. et al. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91, 209-219 (1997).
44. KIP1 degradation and induces S phase in quiescent cells. Nature Cell Biol. 1, 207-214 (1999).
45. Carrano, A. C. et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1, 193-199 (1999).
46. Tsvetkov, L. M. et al. p27(KIP1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9, 661-664 (1999).
47. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-720 (1996).
48. Kip1. Cell 85, 721-732 (1996).
49. Kip1-deficient mice. Cell 85, 733-744 (1996).
50. Brugarolas, J. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency Nature 377, 552-557 (1995).
51. CIP1/WAF1 undergo normal development but are defective In G1 checkpoint control. Cell 82, 675-684 (1995).
52. Waga, S. et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578 (1994).
53. CIP1. Nature 375, 159-161 (1995).
54. Halevy, O. et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267, 1018-1021 (1995).
55. CIP1 in muscle and other terminally differentiating cells. Science 267, 1024-1027 (1995).
56. Firpo, E. et al. inactivation of a Cdk2 inhibitor during IL-2 induced proliferation of human T-lymphocytes. Mol. Cell. Biol. 14, 4889-4901 (1994).
57. KIP1 cyclin-CDK kinase inhibitor prevented by rapamycin. Nature 372, 570-573 (1994).
58. KIP1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880 (1996).
59. KIP1) of cyclin-dependent kinase 4 activation. Cell 79, 487-489 (1994).
60. Reynisdóttir, I. et al. KIP/CIP and INK4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9, 1831-1845 (1995).
61. Gordon, D. et al. Cell proliferation in human coronary arteries. Proc. Natl Acad. Sci. USA 87, 4600-4604 (1990).
62. Koyama, H. et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of CDK2 inhibitors. Cell 87, 1069-1078 (1996).
63. INK4 on vascular smooth muscle cell proliferation. Circulation 101, 2022-2025 (2000).
64. Yang, Z. Y. et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl Acad. Sci. USA 93, 7905-7910 (1996).
65. Chang, M. W. et al. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 Inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest, 96, 2260-2268 (1995).
66. CIP1 loci accelerates cellular proliferation and impairs arterial wound repair. Circulation 104, 1553 (2001).
67. Smith, S. C. et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 37, 2215-2238 (2001).
68. Sigwart, U. et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316, 701-706 (1987).
69. Vezina, C., Kudelski, A. & Sehgal S. N. Rapamycin (AY-22, 989), a new antifungal antibiotic. I: Toxoneme of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721-726 (1975).
70. Sehgal, S. N., Baker, H. & Vezina, C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II: Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 721-726 (1975).
71. Marks, A. R. Cellular functions of the immunophilins. Physiol. Rev. 76, 631-649 (1996).
72. Marx, S. O. et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76, 412-417 (1995).
73. Poon, M. et al. Rapamycin inhibits smooth muscle cell migration. J. Clin. Invest. 98, 2277-2283 (1996).
74. Bierer, B. E. et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl Acad. Sci. USA 87, 9231-9235 (1990).
75. Morris, R. et al. Rapamycin (sirolimus) inhibits vascular smooth muscle cell DNA synthesis in vitro and suppresses narrowing in arterial allografts, and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant. Proc. 27, 430-431 (1995).
76. Gallo, R. et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by rapamycin. Circulation 99, 2164-2170 (1998).
77. KIP1. Mol. Cell. Biol. 16, 6744-6751 (1995).
78. KIP1 in vascular smooth muscle cell migration. Circulation 103, 2967-2972 (2001).
79. Sousa, J. E. et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. Circulation 103, 192-195 (2001).
80. Sousa, J. E. et al. Sustained suppression of neointimal proliferation by Sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104, 2007-2011 (2001).
81. Morice, M. C. et al. A randomized (double blind) study with the Sirolimus coated BX velocity balloon expandable stent (CYPHER) in the treatment of patients with de novo native coronary artery lesions. [online] (cited 24 Jun 2002) www.clinicaltrialresults.org (2002).
82. Morice, M. C. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 23, 1773-1780 (2002).
83. Wani, M. C. et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-2327 (1971).
84. Schiff, P. B. & Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77, 1561-1565 (1980).
85. Rowinsky, E. K. & Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
86. Walsh, V. & Goodman, J. The billion dollar molecule: taxol in historical and theoretical perspective. Clio. Med. 66, 245-267 (2002).
87. Sollott, S. J. et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95, 1869-1876 (1995).
88. Heldman, A. W. et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103, 2289-2295.
89. Ogawa, M. Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844-2853 (1993).
90. Mauch, P., Ferrara, J. & Hellman, S. Stem cell self-renewal considerations in bone marrow transplantation. Bone Marrow Transplant. 4, 601-607 (1989).
91. Gardner, R. V., Astle, C. M. & Harrison, D. E. Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy. Exp. Hematol. 25, 495-501 (1997).
92. Dao, M. A., Taylor, N. & Nolta, J. A. Reduction in levels of the cyclin-dependent kinase inhibitor p27(KIP-1) coupled with transforming growth factor-β neutralization induces cell-cycle entry and Increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl Acad. Sci. USA 95, 13006-13011 (1998).
93. di1 and p27(KIP1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood 93, 4167-4178 (1999).
94. Yaroslavskiy, B. et al. Subcellular and cell-cycle expression profiles of CDK-inhibitors, in normal differentiating myeloid cells. Blood 93, 2907-2917 (1999).
95. CIP1 in the maintenance of stem/progenitor cells in vivo. Blood 88, 3710-3719 (1996).
96. cip1/waf1 in the colony formation from murine myeloid progenitor cells as assessed by retroviral-mediated gene transfer. Blood Cells Mol. Dis. 24, 138-148 (1998).
97. cip1/waf1. Science 287, 1804-1808 (2000).
98. + cells while maintaining primitive hematopoietic potential. Exp. Hematol. 26, 6884-6888 (1998).
99. KiP1. Nature Med. 6, 1235-1240 (2000).
100. KIP1 safeguards against inflammatory injury. Nature Med. 4, 575-580 (1998).
101. Schwartz, R. H. T-cell clonal anergy. Curr. Opin. Immunol. 9, 351-357 (1997).
102. KIP1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nature Med. 6, 290-297 (2000).
103. Aikawa, T. Segre, G. V. & Lee, K. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-CDK2. J. Biol. Chem. 276, 29347-29352 (2001).
104. Missero, C. et al. Involvement of the cell-cycle inhibitor CIP1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl Acad. Sci. USA 92, 5451-5455 (1995).
105. CIP1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 10, 3065-3075 (1996).
106. WAF1/CIP1 expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp. Cell Res. 227, 171-181 (1996).
107. CIP1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280, 1069-1072 (1998).
108. WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int. 56, 1691-1699 (1999).
109. Wang, J. & Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273, 359-361 (1996).
110. WAF1/CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J. Am. Soc. Nephrol. 9, 986-993 (1998).
111. WAF1/CIP1 functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc. Natl Acad. Sci. USA 96, 9089-9094 (1999).
112. Sherr, C. J. Cancer cell cycles. Science 274, 1672-1677 (1996).
113. Tsihlias, J., Kapusta, L. & Slingerland, J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50, 401-423 (1999).
114. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
115. Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: emerging patterns from diverging signals. Genes Dev. 12, 2973-2983 (1998).
116. Weinberg, R. A. The retinoblastoma gene and cell cycle control. Cell 81, 323-330 (1995).
117. Sherr, C. J. The INK4A/ARF network in tumour suppression. Nature Rev. Mol. Cell Biol. 2, 731-737 (2001).
118. Sionov, R. V. & Haupt, Y. The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157 (1999).
119. Bates, S. & Vousden, K. H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 55, 28-37 (1999).
120. Zhang, Y. & Xiong, Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12, 175-186 (2001).
121. Quelle, D. E. et al. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
122. Weichselbaum, R. R. & Kufe, D. Gene therapy of cancer. Lancet 349, 10-12 (1997).
123. Chen, Y. N. et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl Acad. Sci. USA 96, 4325-4329 (1999).
124. Fischer, P. M. & Lane, D. P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 7, 11213-11245 (2000).
125. Senderowicz, A. M. et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 16, 2986-2929 (1998).
126. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19, 6600-6606 (2000).
127. Fischer, P. M. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Discov. Dev. 4, 623-634 (2001).
128. Ball, K. L. et al. Cell-cycle arrest and inhibition of CDK4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 7, 71-80 (1997).
129. Fahraeus, R. et al. New approaches to cancer therapies. J. Pathol. 187, 138-146 (1999).
130. Sharma, S. K. et al. Identification of E2F-1/Cyclin A antagonists. Bioorg. Med. Chem. Lett. 11, 2449-2452 (2001).
131. Cohen, B. A., Colas, P. & Brents, P. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl Acad. Sci. USA 95, 14272-14277 (1998).
132. Colas, P. Combinatorial protein reagents to manipulate protein function. Curr. Opin. Chem. Biol. 4, 54-59 (2000).
133. Donnellan, R. & Chetty, R. Cyclin E in human cancers. FASEB J. 13, 773-780 (1999).
134. Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231-234 (1997).
135. KIP1 protein: prognostic implications in primary breast cancer. Nature Med. 3, 227-230 (1997).
136. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222-225 (1997).
137. Schwarze, S. R. et al. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20, 8184-8194 (2001).
138. KIP1 is haplo-insufficient for tumour suppression. Nature 396, 177-180 (1998).
139. Davis, S. T. et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291, 134-137 (2001).
140. Boehm, M. & Nabel, E. G. Cell cycle and cell migration. Circulation 103, 2879-2881 (2001).
141. Sherr, C. J. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695 (2000).